Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subject whose age is 20 \~ 45 at the time of screening visit.~* Body weight of ≥50kg and \<90kg, while within ±20% of the ideal body weight. \[ideal body weight(kg) = {height(cm)-100}x 0.9\]~* Subject agreed to participate in the trial and to follow all of trial-related rules with a full understanding, after having a full account of the trial~Exclusion Criteria:~* Present disease(s) or medical history(ies) which is(are) clinically significant on liver, heart, nervous system, respiratory system, haemato-oncology, cardiovascular or psychopathy.~* Diagnosed or suspected infectious disease within 30 days in prior to the administration.~* Clinically significantly allergic to drug(s) containing AI of N-Rephasin® SAL200 or to other drugs including aspirin and antibiotics, or has medical history(ies) on such allergy.~* Already has taken other drug(s) containing AI of N-Rephasin® SAL200.~* Positive for Antibody of N-Rephasin® SAL200.~* SBP≤90mmHg or DBP≤50mmHg, otherwise, SBP≥150mmHg or DBP≥100mmHg in Vital sign which was measured after taking 3 minutes of resting in sitting position.~* Has medical history of drug abuse or positive to drug abuse in urine drug screening.~* Has taken any prescription drug(s) or herbal medicine(s) within 14 days prior to the administration, otherwise, any OTC(Over the counter) (s) or vitamin(s) within 7 days prior to the administration(However, can participate in the study if investigator makes a decision that the subject can participate regardless the drug taken).~* Has taken any other study drugs within 2 months prior to the administration.~* Has donated blood(whole blood donation or component transfusion) within (2 months or 1 month, respectively) in prior to the administration, otherwise, has received blood transfusion within 1 month in prior to the administration.~* Smoke at present or positive to metabolism of nicotine in urine test.~* Drink regularly(over 21 units/week, 1 unit= 10 g of pure alcohol), otherwise, is not able to interrupt drinking and smoking in study period.~* Investigator made a decision that the subject is not eligible based on results of laboratory test or other reason.~* Not agree with contraception for 60days after the administration, otherwise, notification of pregnancy in case of his partner is pregnant for 90 days after the administration.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- N-Rephasin® SAL200 (Type: EXPERIMENTAL): N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
- INT200-Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).